2016
Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection
Lauretti F, Chattopadhyay A, de Oliveira França RF, Castro-Jorge L, Rose J, da Fonseca BA. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection. Human Vaccines & Immunotherapeutics 2016, 12: 2327-2333. PMID: 27185081, PMCID: PMC5027729, DOI: 10.1080/21645515.2016.1183857.Peer-Reviewed Original ResearchConceptsVaccine candidatesBALB/c miceImportant arbovirus diseaseCellular immune responsesDENV-2 infectionDengue-2 virusDENV vaccineHemorrhagic casesVSV virusesSubcutaneous routeHumoral responseC miceClinical trialsLethal infectionImmune responseDENV-2Vaccine vectorControl groupVirus expressionVaccineE expressionMiceFirst inoculationLethal dosesChallenge experiments
2012
A Chimeric Vesiculo/Alphavirus Is an Effective Alphavirus Vaccine
Chattopadhyay A, Wang E, Seymour R, Weaver SC, Rose JK. A Chimeric Vesiculo/Alphavirus Is an Effective Alphavirus Vaccine. Journal Of Virology 2012, 87: 395-402. PMID: 23077320, PMCID: PMC3536361, DOI: 10.1128/jvi.01860-12.Peer-Reviewed Original ResearchConceptsChikungunya virusVesicular stomatitis virusChimeric vesicular stomatitis virusAlphavirus vaccinesCellular immune responsesAlphavirus chikungunya virusMosquito-transmitted alphavirusCHIKV glycoproteinsCHIKV infectionCHIKV vaccineLicensed vaccineSingle doseWorldwide epidemicChikungunya feverImmune responseExperimental vaccinesAlphavirus infectionMultiple recent outbreaksVaccineHigh titersChimeric virusesSerious human diseasesVSV glycoproteinVirusRecent outbreak
2010
Complementing Defective Viruses That Express Separate Paramyxovirus Glycoproteins Provide a New Vaccine Vector Approach
Chattopadhyay A, Rose JK. Complementing Defective Viruses That Express Separate Paramyxovirus Glycoproteins Provide a New Vaccine Vector Approach. Journal Of Virology 2010, 85: 2004-2011. PMID: 21177820, PMCID: PMC3067786, DOI: 10.1128/jvi.01852-10.Peer-Reviewed Original Research
2008
Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection
Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK. Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine 2008, 26: 6329-6337. PMID: 18832004, PMCID: PMC2628553, DOI: 10.1016/j.vaccine.2008.09.031.Peer-Reviewed Original ResearchConceptsTime of challengeVesicular stomatitis virusVaccine protectionAnti-LcrV antibodySingle-dose protectionDepletion of CD4Recombinant vesicular stomatitis virusYersinia pestis challengeCellular immunityAntibody titersSingle doseIgG1 isotypePlague vaccineLcrV proteinOptimal protectionPlague challengeCD4Stomatitis virusCellsCD8IgG2aVaccineMiceDoseTiters